United Therapeutics Corp: evp & gc Paul A. Mahon exercised 8,300 shares

What happened

• Paul A. Mahon, evp & general counsel, exercised options for 8,300 shares at $146.03 on Oct 15, 2026 (acquired for $1,212,049) and the filing reports sales of the resulting 8,300 shares the same day in multiple open-market trades, totaling $4,517,708. The filing also includes a derivative conversion entry for 8,300 shares at $0.00 (internal reporting of option conversion).

Key details

• Transaction date: Oct 15, 2026.
• Option exercise: 8,300 shares acquired at $146.03 for $1,212,049 (code M).
• Sales (code S): 268 shares at $541.64 ($145,160); 1,924 shares at $542.49 ($1,043,753); 1,983 shares at $543.56 ($1,077,871); 791 shares at $544.85 ($430,975); 2,615 shares at $545.69 ($1,426,972); 719 shares at $546.56 ($392,977). Total sale proceeds reported: $4,517,708.
• The filing also shows an option conversion/disposition line for 8,300 shares at $0.00 (reported as derivative disposal).
• Footnotes: F1 states the exercise and sale were pursuant to a pre-arranged 10b5-1 plan entered Aug 11, 2025. F2–F7 note that several sale tranches were executed in multiple trades at price ranges (prices above are weighted averages); full trade-by-trade details are available upon request to the SEC staff, the issuer or a security holder.
• Shares owned after the transaction: not reported in the information provided in this filing.
• Filing date: Oct 16, 2026, reporting transactions on Oct 15, 2026 (no late-file indication in the provided data).

Why it may matter

• The filing shows options were exercised and the resulting shares were sold the same day under a pre-arranged 10b5-1 plan (i.e., shares were sold rather than held).
• A filing does not show why the insider traded or why the company acted.